EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form

Keyword(s):

Human Metabolites

Molecule Category

Free-form


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	RRRKUEQTSCNVJD-UHFFFAOYSA-N
Smiles	OP(O)(=O)OCC(COP(O)(O)=O)(CSCCC(F)(F)C(F)(F)F)CSCCC(F)(F)C(F)(F)F
InChI	InChI=1S/C13H20F10O8P2S2/c14-10(15,12(18,19)20)1-3-34-7-9(5-30-32(24,25)26,6-31-33(27,28)29)8-35-4-2-11(16,17)13(21,22)23/h1-8H2,(H2,24,25,26)(H2,27,28,29)

InChI Key

RRRKUEQTSCNVJD-UHFFFAOYSA-N

Smiles

OP(O)(=O)OCC(COP(O)(O)=O)(CSCCC(F)(F)C(F)(F)F)CSCCC(F)(F)C(F)(F)F

InChI

InChI=1S/C13H20F10O8P2S2/c14-10(15,12(18,19)20)1-3-34-7-9(5-30-32(24,25)26,6-31-33(27,28)29)8-35-4-2-11(16,17)13(21,22)23/h1-8H2,(H2,24,25,26)(H2,27,28,29)

Property Name	Value
Molecular Formula	C13H20F10O8P2S2
Molecular Weight	619.99
AlogP	4.83
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	16.0
Polar Surface Area	133.52
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	35.0

Property Name

Value

Molecular Formula

C13H20F10O8P2S2

Molecular Weight

619.99

AlogP

4.83

Hydrogen Bond Acceptor

6.0

Hydrogen Bond Donor

4.0

Number of Rotational Bond

16.0

Polar Surface Area

133.52

Molecular species

None

Aromatic Rings

0.0

Heavy Atoms

35.0

Resources	Reference
NORMAN SUSDAT

Resources

Reference

NORMAN SUSDAT


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

{3-[(3,3,4,4,4-PENTAFLUOROBUTYL)SULFANYL]-2-{[(3,3,4,4,4-PENTAFLUOROBUTYL)SULFANYL]METHYL}-2-[(PHOSPHONOOXY)METHYL]PROPOXY}PHOSPHONIC ACID

Structure

Physicochemical Descriptors

Cross References